Vitamin K prophylaxis prevents hemorrhagic disease of the newborn.
The present review estimates the potential magnitude of this problem in less developed countries, assessing the need for prophylaxis, along with its cost-effectiveness and feasibility.
Late hemorrhagic disease, occurring between 2 and 12 weeks, often leads to death or permanent disability.
Its median incidence in developed countries is 7 per 100 000 births.
Incidences in less developed countries may be much higher.
Three incidence scenarios are proposed and the corresponding losses of disability-adjusted life-years (DALYs) calculated.
Under the intermediate scenario, late hemorrhagic disease accounts for 0.10% to 0.2% of DALYs lost to children less than 5 years of age.
Assuming a cost of $1.00 per injection, each DALY saved would, cost $133.
Decisions on prophylaxis must be made on a national basis, considering mortality levels and causes, health budgets, and feasibility.
Comparison with the impact of diseases prevented by breast-feeding shows that concern with hemorrhagic disease should not affect breast-feeding promotion efforts, although strategies for supplementing breast-fed infants must be explored.
Mots-clés Pascal : Hémorragie, Déficit, Vitamine K, Chimiothérapie, Traitement, Allaitement, Pays en développement, Prévention, Incidence, Facteur risque, Nouveau né, Homme, Etude comparative, Analyse coût efficacité, Economie santé, Politique sanitaire
Mots-clés Pascal anglais : Hemorrhage, Deficiency, Vitamin K, Chemotherapy, Treatment, Breast feeding, Developing countries, Prevention, Incidence, Risk factor, Newborn, Human, Comparative study, Cost efficiency analysis, Health economy, Health policy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0150596
Code Inist : 002B02G. Création : 21/07/1998.